News & Press

FDA Extends Deadline for Decision on Ipilimumab

November 3, 2010

The U.S Food and Drug Administration (FDA) extended its deadline for an approval decision on Bristol-Myers Squibb’s (BMS) drug for advanced melanoma, ipilimumab.  The FDA was expected to reach a decision by December 25, 2010 but has delayed …

Melanoma Research Gets Boost from Washington, D.C. Patients and Party-goers

November 2, 2010

WASHINGTON, D.C.— For years, treatment options for patients with advanced melanoma have been bleak, with survival averaging around one year after diagnosis.  But as the research community hones in on treatments that may be the first to impro …

MRF to Young Adults: Debunk Melanoma Myths To Increase Survival Odds

October 20, 2010

WASHINGTON, D.C.—Melanoma’s role as the number one form of cancer in young adults may be fueled by pervasive myths and misunderstandings about risk factors, and ways to detect and treat the disease. In 2010 alone, nearly 69,000 America …

Respected Producer/Writer Succumbs to Melanoma

October 7, 2010

The Melanoma Research Foundation (MRF) is deeply saddened to learn of the loss of famed Hollywood producer and writer Stephen J. Cannell, who recently passed away from complications associated with melanoma.  Credited with producing favorites …

The New York Times Publishes MRF Letter to the Editor

September 27, 2010

The MRF submitted a letter to the editor in response to a recent article in The New York Times, “When Testing a Drug Means Withholding It.”  The article focused on the ethics of standard clinical trial protocols in the context of advan …